During the past decade, Endokrinologie Cerny Most sro conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Endokrinologie Cerny Most sro" are "Atherosclerotic Cardiovascular Disease" (1 trials) and "Coronary Heart Disease (CHD)" (1 trials). Many other conditions were trialed in "Endokrinologie Cerny Most sro" in a lesser frequency.

Most popular intervention types in "Endokrinologie Cerny Most sro" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Evolocumab" (1 trials), "Lp(a) Screening" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Endokrinologie Cerny Most sro" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Endokrinologie Cerny Most sro". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Endokrinologie Cerny Most sro, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Endokrinologie Cerny Most sro, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".